Basic Information
| RNALocate ID: | RLID:11001919 |
| RNA Symbol: | hsa-miR-149-5p |
| Localization: | Extracellular vesicle |
RNA Information
| RNA Name: | hsa-miR-149 |
| RNA ID: | miRBase:MIMAT0000450 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 22849433 |
| Tissue/Cell Line: | HEK-293T cells |
| Method: | Next-generation RNA sequencing |
| Description: | The total numbers of reads >15 bp matching each miRNA were calculated. These values were then normalized to number of reads per million mapped (RPMM) in each library, to enable direct comparison of expression levels. As a measure of the relative levels of expression of individual miRNAs in cells and EVs, the log (base two) of the ratio of the read number in EVs over that in cells was calculated (log2 (EV/cell)). The miRNA expression data for cells and EVs is presented in Additional file 1: Table S1. Data are collected from Table S1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001831 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001832 | Mitochondrion | Myotube | 27396686 |
| RLID:01001833 | Mitochondrion | Skeletal muscle cells | 27563705 |
| RLID:01001834 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001835 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11001913 | Exosome | Primary ovarian tumor cells|Serum | 18589210 |
| RLID:11001914 | Exosome | Renal cancer cells | 21670082 |
| RLID:11001915 | Exosome | Breast milk | 22211110 |
| RLID:11001916 | Exosome | Brain tissue | 23382797 |
| RLID:11001917 | Exosome | Plasma | 23663360 |
| RLID:11001918 | Exosome | Serum | 24683445 |
| RLID:11001920 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000098 | Exosome | Endothelial cells|Seminal fluid|Tongue tissue | |
| RLID-D:11000378 | Microvesicle | Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-149-5p | Diffuse large b cell lymphoma | MNDR-E-MI-16311 |
| MNDR | hsa-miR-149-5p | Oral squamous cell carcinoma | MNDR-E-MI-16312 |
| MNDR | hsa-miR-149-5p | Follicular lymphoma | MNDR-E-MI-16313 |
| MNDR | hsa-miR-149-5p | Medulloblastoma | MNDR-E-MI-16314 |
| MNDR | hsa-miR-149-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-16315 |
| MNDR | hsa-miR-149-5p | Lymphoma | MNDR-E-MI-16316 |
| MNDR | hsa-miR-149-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-16317 |
| MNDR | hsa-miR-149-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-16318 |
| MNDR | hsa-miR-149-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-16319 |
| MNDR | hsa-miR-149-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-16320 |
| MNDR | hsa-miR-149-5p | Breast cancer luminal | MNDR-E-MI-16321 |
| MNDR | hsa-miR-149-5p | Anencephaly | MNDR-E-MI-16322 |
| MNDR | hsa-miR-149-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-16323 |
| MNDR | hsa-miR-149-5p | Dermatomyositis | MNDR-E-MI-16324 |
| MNDR | hsa-miR-149-5p | Prostate cancer | MNDR-E-MI-16325 |
| MNDR | hsa-miR-149-5p | Gastric cancer | MNDR-E-MI-16326 |
| MNDR | hsa-miR-149-5p | Alzheimer disease | MNDR-E-MI-16327 |
| MNDR | hsa-miR-149-5p | Intracranial aneurysm | MNDR-E-MI-16328 |
| MNDR | hsa-miR-149-5p | Dysautonomia familial | MNDR-E-MI-16329 |
| MNDR | hsa-miR-149-5p | Polycystic ovary syndrome | MNDR-E-MI-16330 |
| MNDR | hsa-miR-149-5p | Leukemia | MNDR-E-MI-16331 |
| MNDR | hsa-miR-149-5p | Lung cancer | MNDR-E-MI-16332 |
| MNDR | hsa-miR-149-5p | Parkinson disease | MNDR-E-MI-16333 |
| MNDR | hsa-miR-149-5p | Breast cancer | MNDR-E-MI-16334 |
| MNDR | hsa-miR-149-5p | Neuroendocrine neoplasia | MNDR-E-MI-16335 |
| MNDR | hsa-miR-149-5p | Thyroid cancer | MNDR-E-MI-16336 |
| MNDR | hsa-miR-149-5p | Pituitary neoplasms | MNDR-E-MI-16337 |
| MNDR | hsa-miR-149-5p | Pancreatic cancer | MNDR-E-MI-16338 |
| MNDR | hsa-miR-149-5p | Melanoma | MNDR-E-MI-16339 |
| MNDR | hsa-miR-149-5p | Williams syndrome | MNDR-E-MI-16340 |
| MNDR | hsa-miR-149-5p | Rectum adenocarcinoma | MNDR-E-MI-16341 |
| MNDR | hsa-miR-149-5p | Nephroblastoma | MNDR-E-MI-16342 |
| MNDR | hsa-miR-149-5p | Colon cancer | MNDR-E-MI-16343 |
| MNDR | hsa-miR-149-5p | Colon adenocarcinoma | MNDR-E-MI-16344 |
| MNDR | hsa-miR-149-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-16345 |
| MNDR | hsa-miR-149-5p | Familial ovarian cancer | MNDR-E-MI-16346 |
| MNDR | hsa-miR-149-5p | Prostate adenocarcinoma | MNDR-E-MI-16347 |
| MNDR | hsa-miR-149-5p | Pulmonary tuberculosis | MNDR-E-MI-16348 |
| MNDR | hsa-miR-149-5p | Glioblastoma | MNDR-E-MI-16349 |
| MNDR | hsa-miR-149-5p | Astrocytoma | MNDR-E-MI-16350 |
| MNDR | hsa-miR-149-5p | Glioma | MNDR-E-MI-16351 |
| MNDR | hsa-miR-149-5p | Oligodendroglioma | MNDR-E-MI-16352 |
| MNDR | hsa-miR-149-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-16353 |
| MNDR | hsa-miR-149-5p | Osteosarcoma | MNDR-E-MI-16354 |
| MNDR | hsa-miR-149-5p | Liposarcoma | MNDR-E-MI-16355 |
| MNDR | hsa-miR-149-5p | Coronary artery disease | MNDR-E-MI-16356 |
| MNDR | hsa-miR-149-5p | Inclusion body myositis | MNDR-E-MI-16357 |
| MNDR | hsa-miR-149-5p | Breast carcinoma | MNDR-E-MI-16358 |
| MNDR | hsa-miR-149-5p | Infarction middle cerebral artery | MNDR-E-MI-16359 |
| MNDR | hsa-miR-149-5p | Uterine cancer | MNDR-E-MI-16360 |
| MNDR | hsa-miR-149-5p | Cervical adenocarcinoma | MNDR-E-MI-16361 |
| MNDR | hsa-miR-149-5p | Gastric adenocarcinoma | MNDR-E-MI-16362 |
| MNDR | hsa-miR-149-5p | Cervical squamous cell carcinoma | MNDR-E-MI-16363 |
| MNDR | hsa-miR-149-5p | Pituitary adenoma | MNDR-E-MI-16364 |
| MNDR | hsa-miR-149-5p | Lung squamous cell carcinoma | MNDR-E-MI-16365 |
| MNDR | hsa-miR-149-5p | Carcinoma lung non-small-cell | MNDR-E-MI-16366 |
| MNDR | hsa-miR-149-5p | Lung adenocarcinoma | MNDR-E-MI-16367 |
| MNDR | hsa-miR-149-5p | Thyroid carcinoma | MNDR-E-MI-16368 |
| MNDR | hsa-miR-149-5p | Ovarian carcinoma | MNDR-E-MI-16369 |
| MNDR | hsa-miR-149-5p | Bladder urothelial carcinoma | MNDR-E-MI-16370 |
| MNDR | hsa-miR-149-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-16371 |
| MNDR | hsa-miR-149-5p | Carcinoma renal cell | MNDR-E-MI-16372 |
| MNDR | hsa-miR-149-5p | Renal clear cell carcinoma | MNDR-E-MI-16373 |
| MNDR | hsa-miR-149-5p | Cholangiocarcinoma | MNDR-E-MI-16374 |
| MNDR | hsa-miR-149-5p | Esophageal cancer | MNDR-E-MI-16375 |
| MNDR | hsa-miR-149-5p | Lung small cell carcinoma | MNDR-E-MI-16376 |
| MNDR | hsa-miR-149-5p | Synovial sarcoma | MNDR-E-MI-16377 |
| MNDR | hsa-miR-149-5p | T acute lymphoblastic leukemia | MNDR-E-MI-16378 |
| MNDR | hsa-miR-149-5p | Acute t cell leukemia | MNDR-E-MI-16379 |
| MNDR | hsa-miR-149-5p | Hepatocellular carcinoma | MNDR-E-MI-16380 |
| MNDR | hsa-miR-149-5p | Familiar ovarian carcinoma | MNDR-E-MI-16381 |
| MNDR | hsa-miR-149-5p | Malignant pleural mesothelioma | MNDR-E-MI-16382 |
| MNDR | hsa-miR-149-5p | Acute myelocytic leukemia | MNDR-E-MI-16383 |
| MNDR | hsa-miR-149-5p | Colorectal cancer | MNDR-E-MI-16384 |
| MNDR | hsa-miR-149-5p | Nasopharyngeal carcinoma | MNDR-E-MI-16385 |
| MNDR | hsa-miR-149-5p | Acute lymphocytic leukemia | MNDR-E-MI-16386 |
| MNDR | hsa-miR-149-5p | Ependymoma | MNDR-E-MI-16387 |
| MNDR | hsa-miR-149-5p | Cardiomegaly | MNDR-E-MI-16388 |
| MNDR | hsa-miR-149-5p | Nasopharyngeal cancer | MNDR-E-MI-16389 |
| MNDR | hsa-miR-149-5p | Prostatic neoplasms | MNDR-E-MI-16390 |
| MNDR | hsa-miR-149-5p | Stroke | MNDR-E-MI-16391 |
| MNDR | hsa-miR-149-5p | Stroke lacunar | MNDR-E-MI-16392 |
| MNDR | hsa-miR-149-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-16393 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | BBC3 | Homo sapiens | RR00212851 |
TOP